Drug Profile
JCAR 024
Alternative Names: JCAR024; ROR-1 directed CAR-T cell therapy - Juno TherapeuticsLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Haematological-malignancies in USA (Parenteral)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Solid-tumours in USA (Parenteral)
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation